NewsBenzingaPiper Sandler ribadisce il sovrappeso su Axsome Therapeutics, mantiene il target di prezzo a $258 Piper Sandler ribadisce il sovrappeso su Axsome Therapeutics, mantiene il target di prezzo a $258 Benzinga 2026.09.18 16:39 (GMT+0) Open on Benzinga Other news US SOL spot ETFs see single-day total net outflow of $6.7215 million Manus launches AI game creation tool, text descriptions can generate playable web games BNB Chain Opens New Layer 1 NewL1 Community Forum, Testnet Expected to Launch by End of 2026 Inception releases diffusion LLM Mercury 3, supporting 1 million token context Amazon.com, Cleveland-Cliffs, Disc Medicine, Silence Therapeutics and EyePoint: Why These 5 Stocks Are on Investors' Radars Today Sophon mainnet to shut down on Nov. 30, users must withdraw assets by Nov. 25
Amazon.com, Cleveland-Cliffs, Disc Medicine, Silence Therapeutics and EyePoint: Why These 5 Stocks Are on Investors' Radars Today
